AviadoBio has launched its phase 1/2 Aspire-FTD trial in the UK, assessing AVB-101, a gene therapy targeting frontotemporal dementia (FTD) with GRN mutations (FTD-GRN). The Advanced Neurotherapies Centre at Cardiff and Vale University Health Board will provide MRI-guided infusions for UK and international trial participants. The center is one of the first in Europe with this capability. Source: PharmaTimes 15/5/2025